

# Impact of Low Vitamin D Level on Inflammatory Bowel Diseases

**Keywords:** Crohn's disease; Ulcerative colitis; Inflammatory bowel diseases; Vitamin D; Epidemiology; Deficiency

## Introduction

The role of vitamin D in patients with inflammatory bowel diseases (IBD) has been for years underestimated [1]. This fat soluble vitamin is absorbed in jejunum and terminal ileum and directly and indirectly affects enterocytes leading to an increase in calcium absorption from the gastrointestinal tract [2]. The main role of vitamin D is regulation of calcium-phosphate homeostasis [2]. However, recently many studies indicate its pleiotropic effects, which is connected with the presence of vitamin D receptors (VDR) in different tissues [2,3].

Anti-carcinogenic activity of vitamin D comprises promotion of cell differentiation, induction of apoptosis, inhibition of cancer cell proliferation, regulation of expression of different proinflammatory cytokines and growth factors, as well anti angiogenic properties [2,3]. However, the evidence that vitamin D prevents development of colon cancer is inconsistent [3]. It is worth to underline that low serum vitamin D level might also result from many other malignancy risk factors such as: obesity (vitamin D sequestration in adipose tissue), lack of physical activity (less sunlight exposure), and difference in diet habits [3].

The deficiency of vitamin D has an important influence on the immune system function, and may interfere proper cellular immune response, especially of activated VDR-expressing monocytes, macrophages, dendritic cells, and lymphocytes [2,3]. Vitamin D promotes microbial killing in the macrophages and inhibits antigen-presenting capacity of the dendritic cells [3]. Acting through VDR in lymphocytes vitamin D inhibits their proliferation and differentiation to maturity, which results in suppression of the adaptive immune response [3].

Epidemiological studies show that prevalence of vitamin D insufficiency is common in patients with IBD - in children 55.6% of patients with Crohn's disease (CD) and 63.6% of patients with ulcerative colitis (UC) have its sub-optimal ( $\leq 32\text{ng/mL}$ ) serum level [4]. Low vitamin D level, (with insufficiency (20-30ng/mL) in 37% and deficiency ( $<20\text{ ng/mL}$ ) in 23%) is found in 60% of adult IBD patients [5]. Especially exposed to low vitamin D levels are patients with pouchitis-69.4% [6].

The most important risk factors of vitamin D insufficiency comprise: mal absorption, resection of small intestine, decreased sunlight exposure, winter and spring season, higher body mass index Z-score, smoking and higher erythrocyte sedimentation rate [2,4].

In IBD patients hypovitaminosis D is associated with severer course of the disease, enhanced use of medications (corticosteroids, biologics, narcotics), increased risk of surgery

and hospitalizations, and quality of life deterioration [7-9]. Low vitamin D level may also contribute to an increased risk of the CD onset [10]. Ananthakrishnan et al. [10] in a large prospective cohort study showed that each 100-IU/day increase in total vitamin D intake resulted in a 10% reduction in UC risk and a 7% reduction in CD risk [10].

Hypovitaminosis D, as well male gender, Asian ethnicity, and corticosteroids use are risk factors for low bone mineral density in IBD [5].

However, deficiency of vitamin D might be also connected with several nonskeletal effects, for instance an increased risk of Clostridium difficile infection [11]. Ananthakrishnan et al. [11] found that each 1ng/mL increase of vitamin D level in plasma was associated with a 4% reduction in risk of Clostridium difficile infection.

Ananthakrishnan et al. [12] in a large IBD cohort (2809 patients) study showed an increased risk of colon cancer in subjects with vitamin D deficiency ( $<20\text{ng/mL}$ ). Each 1ng/mL increase of vitamin D in plasma was associated with an 8% reduction in risk of colorectal cancer [12].

In view of all the above data, vitamin D supplementation might have an important impact on the course of IBD [1,13]. Jørgensen et al. [13] in a randomized double-blind placebo-controlled trial administered vitamin D at the dose of 1200IU/d to CD patients and after three months they noticed reduced number of disease flares (13% vs. 29% in controls), however, the difference was not statistically significant [13]. Pappa HM et al. [4] in a pediatric group of patients with IBD after supplementation of vitamin D at the dose of 2000IU/d observed a lower level of C-reactive protein and interleukin-6. However, more interventional studies are required to confirm the therapeutic efficacy of vitamin D supplementation in IBD [14]. A target of vitamin D levels between 30 and 50 ng/mL appears to be both safe and have benefits for IBD disease course. Daily vitamin D doses between 1800-10,000IU/d are probably necessary [15].

**Mini Review**

Volume 5 Issue 2 - 2016

**Dorota Cibor\****Department of Gastroenterology, Jagiellonian University Medical College, Poland*

**\*Corresponding author:** Dorota Cibor, Department of Gastroenterology, Jagiellonian University Medical College, Sniadeckich 5 Str, 31-545 Krakow, Poland, Email: dorota.cibor@gmail.com

**Received:** May 27, 2016 | **Published:** August 01, 2016

## References

1. Owczarek D, Rodacki T, Domagala-Rodacka R, Cibor D, Mach T (2016) Diet and nutritional factors in inflammatory bowel diseases. *World J Gastroenterol* 22(3): 895-905.
2. Perzanowska-Brzeszkiewicz K, Marcinowska-Suchowierska E (2012) Vitamin D and gastrointestinal diseases. *Postępy Nauk Medycznych* 3: 247-251.
3. Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MB, et al. (2012) The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. *Endocr Rev* 33(3): 456-492.
4. Pappa HM, Langereis EJ, Grand RJ, Gordon CM (2011) Prevalence and risk factors for hypovitaminosis D in young patients with inflammatory bowel disease: a retrospective study. *J Pediatr Gastroenterol Nutr* 53(4): 361-364.
5. Abraham BP, Prasad P, Malaty HM (2014) Vitamin D deficiency and corticosteroid use are risk factors for low bone mineral density in inflammatory bowel disease patients. *Dig Dis Sci* 59(8): 1878-1884.
6. Khann R, Wu X, Shen B (2013) Low levels of vitamin D are common in patients with ileal pouches irrespective of pouch inflammation. *J Crohns Colitis* 7(7): 525-533.
7. Kabbani TA, Koutroubakis IE, Schoen RE, Ramos-Rivers C, Shah N, et al. (2016) Association of vitamin D level with clinical status in inflammatory bowel disease: a 5-year longitudinal study. *Am J Gastroenterol* 111(5): 712-719.
8. Jorgensen SP, Hvas CL, Agnholt J, Christensen LA, Heickendorff L, et al. (2013) Active Crohn's disease is associated with low vitamin D levels. *J Crohns Colitis* 7(10): 407-413.
9. Hlavaty T, Krajcovicova A, Koller T, Toth J, Nevidanska M, et al. (2014) Higher vitamin D serum concentration increases health related quality of life in patients with inflammatory bowel diseases. *World J Gastroenterol* 20(42): 15787-15796.
10. Ananthakrishnan AN, Khalili H, Higuchi LM, Bao Y, Korzenik JR (2012) Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. *Gastroenterology* 142(3): 482-489.
11. Ananthakrishnan AN, Cagan A, Gainer VS, Cheng SC, Cai T (2014) Higher plasma vitamin D is associated with reduced risk of *Clostridium difficile* infection in patients with inflammatory bowel diseases. *Aliment Pharmacol Ther* 39(10): 1136-1142.
12. Ananthakrishnan AN, Cheng SC, Cai T, Cagan A, Gainer VS (2014) Association between reduced plasma 25-hydroxy vitamin D and increased risk of cancer in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol* 12(5): 821-827.
13. Jorgensen SP, Agnholt J, Glerup H, Lyhne S, Villadsen GE (2010) Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study. *Aliment Pharmacol Ther* 32(3): 377-383.
14. Ananthakrishnan AN (2016) Editorial: Vitamin D and IBD: can we get over "causation" hump? *Am J Gastroenterol* 111(5): 720-722.
15. Hlavaty T, Krajcovicova A, Payer J (2015) Vitamin D therapy in inflammatory bowel diseases: who, in what form, and how much? *J Crohns Colitis* 9(2): 198-209.